Affordable Access

deepdyve-link
Publisher Website

Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital.

Authors
  • Karki, Apurwa1
  • Thurm, Craig1
  • Cervellione, Kelly2
  • 1 Department of Pulmonary Medicine, Jamaica Hospital Medical Center, Jamaica, NY, USA. , (Jamaica)
  • 2 Department of Clinical Research, Jamaica Hospital Medical Center, Jamaica, NY, USA. , (Jamaica)
Type
Published Article
Journal
Journal of Community Hospital Internal Medicine Perspectives
Publisher
Informa UK (Taylor & Francis)
Publication Date
Jan 01, 2017
Volume
7
Issue
5
Pages
300–302
Identifiers
DOI: 10.1080/20009666.2017.1374107
PMID: 29147471
Source
Medline
Keywords
License
Unknown

Abstract

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is an organism causing significant mortality and morbidity with nosocomial infections. Ceftaroline is a new cephalosporin antibiotic that has activity against MRSA. In the USA, this antibiotic has not been approved for use in pneumonia caused by MRSA. Objectives: To review the use of ceftaroline in MRSA pneumonia in a US hospital and evaluate its clinical success. Methods: A retrospective study was conducted in an urban community hospital assessing the use of ceftaroline for MRSA pneumonia. Results: The clinical success was comparable to the currently approved treatment for MRSA pneumonia. Conclusion: The results of our study showed a favorable result for the treatment of MRSA pneumonia. Well-designed studies need to be performed for further validation of these results.

Report this publication

Statistics

Seen <100 times